TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03215108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Retrograde CholangioPancreatography(ERCP)
Description: This study is prospective randomized multicenter study by using Endoscopic Retrograde CholangioPancreatography(ERCP). Comparison between Novel flower-type covered stent and Conventional covered stent in malignant extrahepatic biliary obstruction will be conducted after stent insertion by using Endoscopic Retrograde CholangioPancreatography(ERCP).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Retrograde CholangioPancreatography(ERCP)
Description: This study is prospective randomized multicenter study by using Endoscopic Retrograde CholangioPancreatography(ERCP). Comparison between Novel flower-type covered stent and Conventional covered stent in malignant extrahepatic biliary obstruction will be conducted after stent insertion by using Endoscopic Retrograde CholangioPancreatography(ERCP).
Study: NCT03344445

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video-assisted pre anesthesia explain
Description: Anesthesiologist will visit all study patients, and only the experimental group will read the video.
Study: NCT01951846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Study: NCT00394056

Intervention type: DRUG
Group type: OTHER
Intervention: Vestipitant
Description: NK1 receptor antagonist

Intervention type: DRUG
Group type: OTHER
Intervention: Vestipitant
Description: NK1 receptor antagonist

Intervention type: DRUG
Group type: OTHER
Intervention: Vestipitant + Paroxetine
Description: NK1 receptor antagonist and SSRI

Intervention type: DRUG
Group type: OTHER
Intervention: Vestipitant + Paroxetine
Description: NK1 receptor antagonist and SSRI

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo
Study: NCT04669236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention to promote healthy sleep behavior
Description: An action group (6 - 8 pupils) was conducted at each school. Brainstorm sessions about effective strategies to change sleeping behavior in this population were held. Strategies, perceived as effective by the target population, will be summarized in an overview. Also feedback of adolescent, who are not part of the action group, will be asked. After feedback, the intervention will be developed by the intervention schools. Thereby, three different intervention strategies will be implemented and tested (one intervention at each school) to meet the individuals needs of each school. The action groups will develop the intervention materials during sessions this year. Afterwards, they will implement the intervention themselves in collaboration with teachers of the school and the researchers.
Study: NCT01079637

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery with Midfoot Fusion Bolt
Description: Surgery with Midfoot Fusion Bolt

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cast treatment
Description: Cast treatment
Study: NCT03055949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early rehabilitation program
Description: The investigators evaluated patients who were admitted SICU for more than 3 days for an early rehabilitation program and delivered one of 5-stepped rehabilitation program if the patient was eligible.
Study: NCT01079442

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative coffee
Description: schedule for coffee administration for the present trial was chosen as follows (starting 6 hours postoperatively):~* 08:00 100mL beverage~* 12:00 100mL beverage~* 16:00 100mL beverage

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: water
Description: The control drink consists of 100 ml warm water which is administered according a same fixed schedule as Group A starting 6 hours postoperatively:~* 08:00 100mL beverage~* 12:00 100mL beverage~* 16:00 100mL beverage
Study: NCT03711409

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soft tissue biased manual therapy group
Description: It includes hot pack and muscle release technique of pectoralis major, pectoralis minor, teres major, teres minor, infraspinatus and posterior deltoid muscles. Subjects are supine on the bed. The muscle release technique is applied at the end available range and the acceptable intensity. The time of muscle release intervention is about 30 min and hot-pack about 15 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy group
Description: It includes modality (electrotherapy, ultrasound and low-level laser therapy) and GH joint mobilization. GH joint mobilization includes anterior to posterior glide, caudal glide and distraction. The intensity of joint mobilization is grade III to IV. The time of joint mobilization is about 30 min and hot-pack for 15 min.
Study: NCT03527745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Single dose of albendazole (200mg, dependent on treatment cohort)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Single dose of albendazole (400mg, dependent on treatment cohort)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Single dose of albendazole (600mg, dependent on treatment cohort)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Single dose of albendazole (800mg, dependent on treatment cohort)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets will be obtained from Fagron, Germany.
Study: NCT01402037

Intervention type: DRUG
Group type: OTHER
Intervention: Glucose
Description: Glucose 20% intravenous

Intervention type: DRUG
Group type: OTHER
Intervention: Glucose
Description: Glucose 20% intravenous

Intervention type: DRUG
Group type: OTHER
Intervention: Glucose
Description: Glucose 20% intravenous

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous glucose monitoring
Description: Blood glucose profiles: during 5 days glucose profiles will be determined by seven-point self-monitoring of blood glucose (SMBG) (pre-breakfast: assumed time 7 am, post-breakfast: 8.30 am, pre-lunch: 12 am, post-lunch: 1.30 pm, pre-supper: 6 am, post-supper: 7.30 pm, bedtime: 10 pm) and by continuous glucose monitoring (CGM). Participants will be blinded for the CGM results.

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous glucose monitoring
Description: Blood glucose profiles: during 5 days glucose profiles will be determined by seven-point self-monitoring of blood glucose (SMBG) (pre-breakfast: assumed time 7 am, post-breakfast: 8.30 am, pre-lunch: 12 am, post-lunch: 1.30 pm, pre-supper: 6 am, post-supper: 7.30 pm, bedtime: 10 pm) and by continuous glucose monitoring (CGM). Participants will be blinded for the CGM results.

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous glucose monitoring
Description: Blood glucose profiles: during 5 days glucose profiles will be determined by seven-point self-monitoring of blood glucose (SMBG) (pre-breakfast: assumed time 7 am, post-breakfast: 8.30 am, pre-lunch: 12 am, post-lunch: 1.30 pm, pre-supper: 6 am, post-supper: 7.30 pm, bedtime: 10 pm) and by continuous glucose monitoring (CGM). Participants will be blinded for the CGM results.

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous glucose monitoring
Description: Blood glucose profiles: during 5 days glucose profiles will be determined by seven-point self-monitoring of blood glucose (SMBG) (pre-breakfast: assumed time 7 am, post-breakfast: 8.30 am, pre-lunch: 12 am, post-lunch: 1.30 pm, pre-supper: 6 am, post-supper: 7.30 pm, bedtime: 10 pm) and by continuous glucose monitoring (CGM). Participants will be blinded for the CGM results.
Study: NCT04415125

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Applying on-ice and off-ice performance tests
Description: The subjects were given a written description of study procedures and potential risks.The athletes'history of injury including previous injury site, type, number, date, surgical status, time to return to the field after the injury and the mechanism of injury were recorded. The subjects completed off-ice performance measures followed by on-ice testing with time allotted for warm-up before both the off-ice and on-ice testing.
Study: NCT04642950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: 250 μg/vial of sargramostim will be dissolved in 4 mL of physiological saline and 125 μg of which will be administered using inhaler twice daily in approximately 10-15 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 mL of physiological saline will be administered using inhaler twice daily in approximately 10-15 minutes.
Study: NCT01242280

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent
Description: Self-expandable esophageal stent (SX-Danis, Czesc Republic).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tamponade
Description: Sengstaken-Blakemore tube
Study: NCT04173754

Intervention type: PROCEDURE
Intervention: Motion Style Acupuncture Treatment(MSAT)
Description: Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
Study: NCT03781700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 5 milligram tablets, 1 milligram per kilogram bodyweight per orally per day during 10 days, maximum 50 milligram per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablets with identical appearance to the experimental drug
Study: NCT02815969

Intervention type: OTHER
Intervention: vena punction
Description: vena punction and urine collection

Intervention type: OTHER
Intervention: vena punction
Description: vena punction and urine collection
Study: NCT03874130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scopolamine
Description: IV Scopolamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scopolamine
Description: IV Scopolamine
Study: NCT04232605

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1 peptide
Description: Receive intravenous infusion of GLP-1. The dosage will be determined after a dose finding pilot study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Receive intravenous infusion saline
Study: NCT04524065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early rehabilitation protocol for children hospitalized in the PICU
Description: The early rehabilitation protocol was developed by a collaborative multidisciplinary team approach in Samsung Medical Center, and the central components include the involvement of physical therapy/occupational therapy (PT/OT).
Study: NCT04000503

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-collected HPV testing for cervical cancer screening
Description: Self-collection cervical cancer screening, STI screening, and education on HIV by a community health worker. Women who test positive for high-risk HPV types will be referred to a designated health centre for VIA follow-up and treatment if indicated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-collected HPV testing for cervical cancer screening
Description: Self-collection cervical cancer screening, STI screening, and education on HIV by a community health worker. Women who test positive for high-risk HPV types will be referred to a designated health centre for VIA follow-up and treatment if indicated.
Study: NCT03443778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.5%
Description: Marcaine 0.5% Injectable Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.5% , Dexamethasone
Description: Bupivacaine 0.5% , Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nacl 0,9 %
Description: Injectable Solution
Study: NCT02788461

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiotherapy
Description: Patients will receive radiotherapy of 60Gy in 30 fractions (5x per week) with concurrent cisplatin and etoposide chemotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy with Integrated Boost Dose
Description: Patients will receive an RT integrated boost to tumor subvolumes (max boost dose of 85Gy) in 30 fractions (5x per week) with concurrent cisplatin and etoposide chemotherapy.
Study: NCT04010799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 6333
Description: CHF 6333 - Part I - SAD CHF 6333 - Part II - MD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - Part I - SAD Placebo Part II - MAD
Study: NCT02296775

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DRL_RI
Description: Two 1000 mg intravenous infusions, one each on Day 1 and Day 15

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituxan
Description: Two 1000 mg intravenous infusions, one each on Day 1 and Day 15

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MabThera
Description: Two 1000 mg intravenous infusions, one each on Day 1 and Day 15
Study: NCT00118053

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: herceptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Modified radical mastectomy or lumpectomy and axillary node dissection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Whole breast or chest wall irradiation (as determined by radiologist)
Study: NCT02132247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac hydroxyethylpyrrolidine
Study: NCT03263299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cabergoline
Description: Cabergoline was administered in a dose of 1 mg/week in two divided doses which was terminated after embryo transfer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH agonist
Description: Microdose flare-up regimen. The patient received diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation is initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH agonist
Description: Microdose flare-up regimen. The patient received diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation is initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH agonist
Description: Microdose flare-up regimen. The patient received diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation is initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day.
Study: NCT00763022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-559
Description: TAK-559 16 mg, tablets, orally, once daily for up to 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-559
Description: TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.
Study: NCT04182009

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omron NE-U17 Ultrasonic nebuliser
Description: The Omron Ultrasonic nebuliser dispenses sterile saline from a medication cup as an aerosol, which is inhaled.

Intervention type: DEVICE
Group type: OTHER
Intervention: Omron NE-U17 Ultrasonic nebuliser
Description: The Omron Ultrasonic nebuliser dispenses sterile saline from a medication cup as an aerosol, which is inhaled.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Akita Jet Inhalation System
Description: The Akita Jet Inhalation System is a breath actuated nebuliser, which works with a positive pressure.

Intervention type: DEVICE
Group type: OTHER
Intervention: Akita Jet Inhalation System
Description: The Akita Jet Inhalation System is a breath actuated nebuliser, which works with a positive pressure.
Study: NCT01891409

Intervention type: DEVICE
Group type: OTHER
Intervention: Male circumcision using the Shang Ring device
Study: NCT02886078

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dorsal approach CapFlex arthroplasty
Description: Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the dorsal approach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Volar approach CapFlex arthroplasty
Description: Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the volar approach.
Study: NCT02582970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Intravenous 5-fluorouracil based chemotherapy will be administered until disease progression or until termination of the study. The chemotherapy regimen will be at the discretion of the prescriber and will not be provided by the sponsor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered IV 5 mg/kg every 2 weeks until disease progression or until termination of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be administered at the discretion of the prescriber until disease progression or until termination of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered at the discretion of the prescriber until disease progression or until termination of the study.
Study: NCT02384616

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Delivery of high concentration of oxygen at induction, maintenance and extubation of children under general anesthesia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Delivery of high concentration of oxygen at induction, maintenance and extubation of children under general anesthesia.
Study: NCT04338867

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole-brain radiotherapy
Description: Patients were randomized 1:1 and allocated to either the control arm who received whole-brain radiotherapy (WBRT) or the experimental arm who received WBRT and the addition 36 mg of transdermal nitroglycerin (TN)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole-brain radiotherapy
Description: Patients were randomized 1:1 and allocated to either the control arm who received whole-brain radiotherapy (WBRT) or the experimental arm who received WBRT and the addition 36 mg of transdermal nitroglycerin (TN)
Study: NCT05577793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother's Voice
Description: The audio recording was made to listen to the baby for 15 minutes during the nasal CPAP application. The NIPS and PICS scores were evaluated and recorded before, during and after the application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother's Voice
Description: The audio recording was made to listen to the baby for 15 minutes during the nasal CPAP application. The NIPS and PICS scores were evaluated and recorded before, during and after the application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch
Description: Therapeutic touch was started 5 minutes before nasal prongs were placed, and was applied for 5 minutes during the application, and continued for another 5 minutes after the nasal prongs were placed. The method was applied for a total of 15 minutes as 5 minutes of hand resting, 5 minutes of gentle caressing and 5 more minutes of hand resting.The NIPS and PICS scores were evaluated and recorded before, during and after the application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch
Description: Therapeutic touch was started 5 minutes before nasal prongs were placed, and was applied for 5 minutes during the application, and continued for another 5 minutes after the nasal prongs were placed. The method was applied for a total of 15 minutes as 5 minutes of hand resting, 5 minutes of gentle caressing and 5 more minutes of hand resting.The NIPS and PICS scores were evaluated and recorded before, during and after the application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother's Voice +Therapeutic Touch
Description: Both applications were applied together for 15 minutes.The NIPS and PICS scores were evaluated and recorded before, during and after the application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother's Voice +Therapeutic Touch
Description: Both applications were applied together for 15 minutes.The NIPS and PICS scores were evaluated and recorded before, during and after the application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: The premature babies in the control group did not receive any intervention other than the hospital procedure.The NIPS and PICS scores were evaluated and recorded before, during and after the application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: The premature babies in the control group did not receive any intervention other than the hospital procedure.The NIPS and PICS scores were evaluated and recorded before, during and after the application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: The premature babies in the control group did not receive any intervention other than the hospital procedure.The NIPS and PICS scores were evaluated and recorded before, during and after the application.
Study: NCT00597194

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hernia repair
Description: Hernia repair laparoscopically (LH) or by open operation (OH)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hernia repair
Description: Hernia repair laparoscopically (LH) or by open operation (OH)
Study: NCT00600925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gentamicin-collagen sponge dipped in saline
Description: 2 gentamicin-collagen sponges inserted before closure of the laparotomy